Refractory to steroids

Alen, Reinila, & Reijo (1985) observed that serum testosterone level tended to increase throughout a 26 week cycle of various AAS until abruptly dropping below normal levels during cessation. When athletes discontinue the use of AAS they experience a refractory period where they do not produce physiological amounts of endogenous testosterone (Di Pasquale, 1992a). Anabolic-androgenic steroid can reduce endogenous testosterone, gonadotrophic hormones and sex hormone-binding globulin (Yesalis, Wright, & Bahrke, 1989). Weight trained athletes have been shown to have low serum testosterone concentrations immediately after cessation of an AAS cycle but return to normal within weeks (Alen, Reinila, & Reijo, 1985).

The most common side effect of topical corticosteroid use is skin atrophy. All topical steroids can induce atrophy, but higher potency steroids, occlusion, thinner skin, and older patient age increase the risk. The face, the backs of the hands, and intertriginous areas are particularly susceptible. Resolution often occurs after discontinuing use of these agents, but it may take months. Concurrent use of topical tretinoin (Retin-A) % may reduce the incidence of atrophy from chronic steroid applications. 30 Other side effects from topical steroids include permanent dermal atrophy, telangiectasia, and striae.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential of ibrutinib and its further development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products or new indications; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Refractory to steroids

refractory to steroids

Media:

refractory to steroidsrefractory to steroidsrefractory to steroidsrefractory to steroidsrefractory to steroids

http://buy-steroids.org